Progenics Pharmaceuticals Inc. (PGNX) Shares Bought by Northern Trust Corp

Northern Trust Corp boosted its position in Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) by 3.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 895,458 shares of the biotechnology company’s stock after purchasing an additional 33,774 shares during the period. Northern Trust Corp owned approximately 1.28% of Progenics Pharmaceuticals worth $6,081,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PGNX. BlackRock Inc. lifted its position in Progenics Pharmaceuticals by 149,468.9% in the first quarter. BlackRock Inc. now owns 9,523,053 shares of the biotechnology company’s stock worth $89,897,000 after purchasing an additional 9,516,686 shares during the period. Eagle Asset Management Inc. lifted its position in Progenics Pharmaceuticals by 50.8% in the second quarter. Eagle Asset Management Inc. now owns 4,012,366 shares of the biotechnology company’s stock worth $27,243,000 after purchasing an additional 1,352,245 shares during the period. Vanguard Group Inc. lifted its position in shares of Progenics Pharmaceuticals by 46.1% during the 1st quarter. Vanguard Group Inc. now owns 4,132,770 shares of the biotechnology company’s stock valued at $39,013,000 after acquiring an additional 1,304,487 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Progenics Pharmaceuticals by 207.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 834,742 shares of the biotechnology company’s stock valued at $7,880,000 after acquiring an additional 563,534 shares during the last quarter. Finally, State Street Corp lifted its position in shares of Progenics Pharmaceuticals by 26.1% during the 1st quarter. State Street Corp now owns 2,598,721 shares of the biotechnology company’s stock valued at $24,534,000 after acquiring an additional 537,739 shares during the last quarter. Hedge funds and other institutional investors own 89.19% of the company’s stock.

Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) opened at $5.28 on Wednesday. Progenics Pharmaceuticals Inc. has a 52-week low of $4.60 and a 52-week high of $11.72. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.86 and a current ratio of 7.86.

Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.02. Progenics Pharmaceuticals had a negative net margin of 445.81% and a negative return on equity of 67.61%. The company had revenue of $2.70 million for the quarter, compared to the consensus estimate of $3.58 million. During the same period in the previous year, the business earned $0.52 EPS. The company’s revenue was down 95.0% on a year-over-year basis. analysts predict that Progenics Pharmaceuticals Inc. will post -0.92 earnings per share for the current fiscal year.

PGNX has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $15.00 price objective on shares of Progenics Pharmaceuticals in a research report on Tuesday, September 5th. Zacks Investment Research downgraded Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 18th. Needham & Company LLC reiterated a “strong-buy” rating and set a $14.00 price objective on shares of Progenics Pharmaceuticals in a research report on Friday, September 1st. ValuEngine upgraded Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, September 18th. Finally, Aegis reiterated a “buy” rating and set a $14.00 price objective on shares of Progenics Pharmaceuticals in a research report on Tuesday, August 22nd. Three analysts have rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $13.20.

TRADEMARK VIOLATION NOTICE: This story was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://sportsperspectives.com/2017/11/15/progenics-pharmaceuticals-inc-pgnx-shares-bought-by-northern-trust-corp.html.

Progenics Pharmaceuticals Profile

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply